FDA expands Xtandi approval to mCSPC
Enzalutamide was previously approved for castration-resistant prostate cancer.
Related Articles
Short telomere length and immunosuppression: Updates in nonidiopathic pulmonary fibrosis, interstitial lung disease
Interstitial lung diseases (ILDs) are a diverse group of relentlessly progressive fibroinflammatory disorders.
Post–intensive care syndrome and insomnia
There has been a recent interest in post–intensive care syndrome (PICS), as an increasing number of patients are surviving critical illness.
Diagnostic yield reporting of bronchoscopic peripheral pulmonary nodule biopsies: A call for standardization
More than 1.5 million Americans are diagnosed with an incidental CT scan-detected lung nodule annually.
Coding & billing: A look into G2211 for visit complexities
CMS creates add-on code ‘to address the additional costs and resources associated with providing longitudinal care.’
Use of albumin in critically ill patients
Even for widely accepted albumin indications, the certainty of evidence is low ands recommendations are weak.
Use of albumin in critically ill patients
Even for widely accepted albumin indications, the certainty of evidence is low ands recommendations are weak.
Use of albumin in critically ill patients
Even for widely accepted albumin indications, the certainty of evidence is low ands recommendations are weak.
Use of albumin in critically ill patients
Even for widely accepted albumin indications, the certainty of evidence is low ands recommendations are weak.
Use of albumin in critically ill patients
Even for widely accepted albumin indications, the certainty of evidence is low ands recommendations are weak.